Thrombolysis in Pediatric Stroke (TIPS)

This study has been terminated.
(Lack of patient accrual)
The Hospital for Sick Children
Medical College of Wisconsin
University of Texas at Austin
Alberta Children's Hospital
McMaster University
Information provided by (Responsible Party):
Catherine Amlie-Lefond, Seattle Children's Hospital Identifier:
First received: May 1, 2012
Last updated: February 10, 2014
Last verified: February 2014

Thrombolysis in Pediatric Stroke (TIPS) is a five-year multi-center international safety and dose-finding study of intravenous (IV) tPA in children with acute ischemic stroke (AIS) to determine the maximal safe dose of intravenous Tissue Plasminogen Activator (IV-tPA) among three doses (0.75. 0.9, 1.0 mg/kg) for children age 2-17 years within 4.5 hours from onset of acute AIS.

Condition Intervention Phase
Drug: Tissue plasminogen activator (Activase®)
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Thrombolysis in Pediatric Stroke (TIPS)

Resource links provided by NLM:

Further study details as provided by Seattle Children's Hospital:

Primary Outcome Measures:
  • Symptomatic Intracranial Hemorrhage [ Time Frame: 36 hours ] [ Designated as safety issue: Yes ]
    Any PH 2 OR, Any intracranial hemorrhage which is judged to be the most important cause of neurological deterioration (a minimum of change of 2 or more points on the PedNIHSS from the lowest PedNIHSS). At the time of each PedNIHSS assessment, the site PI or co-PI will review the patient's course with the care team to ensure that all changes in neurologic status, including improvements since the last assessment by the study team, are captured, OR, Any hemorrhage that results in the need for transfusion, need to discontinue study drug, surgical evacuation of hemorrhage, or death.

Secondary Outcome Measures:
  • 3 month outcome [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    The 3-month neurological outcome in children treated with IV tPA will be determined.

  • Pharmacokinetics of tPA [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
    TIPS will determine the pharmacokinetics of tPA and its inhibitor, plasminogen activator inhibitor, including free tPA, PAI-1, and tPA antigen in children receiving IV tPA for acute AIS. In addition, TIPS will measure the 3-month neurological outcome in children treated with IV tPA.

Enrollment: 1
Study Start Date: October 2012
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tissue plasminogen activator
All patients will receive study drug.
Drug: Tissue plasminogen activator (Activase®)
Investigation labeled tPA will be obtained for all sites by the Core Pharmacy as commercially available recombinant tPA (Genentech as Activase®) for IV administration. The Bayesian method of toxicity probability intervals will be used to select one of the following three dose tiers (0.75, 0.9, 1.0 mg/kg) of IV tPA. The dose escalation for the two age groups (2-10, 11-17 years) will be performed independently. The maximum dose for each tier will be reached at a weight of 90 kg.
Other Name: Genentech as Activase®

  Show Detailed Description


Ages Eligible for Study:   2 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

To be eligible for TIPS, a patient must meet the following Inclusion Criteria:

  1. Age 2 to 17 years inclusive.
  2. Clinical presentation consisting of clearly defined acute onset of neurological deficit in a pattern consistent with arterial territory ischemia.
  3. Clinically significant deficit as defined by a PedNIHSS score of ≥ 6 and ≤ 24 felt to be due to acute stroke that is not improving at the time of initiation of tPA administration
  4. Time of symptom onset within 4.5 hours of initiation of treatment for IV tPA. Time of symptom onset is defined as time the patient was last seen awake and at neurological baseline.
  5. Radiological confirmation of an acute arterial ischemic stroke in one of two ways:

    • MRI confirmation, consisting of acute infarction with restricted diffusion in an arterial territory consistent with the clinical syndrome plus MRA showing partial or complete occlusion in an intracranial artery corresponding to the infarct location, OR,
    • CT and CT angiogram confirmation, consisting of normal head CT or early hypodensity in an arterial territory consistent with the clinical syndrome plus CT angiogram showing partial or complete occlusion in an intracranial artery corresponding to the infarct location.
  6. Baseline neuroimaging (CT or MRI) with no evidence of intracranial hemorrhage (including HI-1, HI-2, PH-1 or PH-2). If no head CT scan is done, the pre-tPA MRI must include Gradient-recalled ECHO (GRE) imaging or Susceptibility Weighted Imaging (SWI) sequences.
  7. Children with seizures at or following onset of stroke may be included, as long as the clinical picture is consistent with the documented arterial occlusion. Patients with the following Exclusion Criteria will not be eligible for TIPS:

Safety Related exclusion criteria:

  1. Patients in whom time of symptom onset is unknown.
  2. Pregnancy
  3. Clinical presentation suggestive of subarachnoid hemorrhage (SAH), even if head CT or head MRI scan is negative for blood.
  4. Patient who would decline blood transfusion if indicated
  5. History of prior intracranial hemorrhage
  6. Known cerebral arterial venous malformation, aneurysm, or neoplasm
  7. Persistent Systolic Blood Pressure > 15% above the 95th percentile for age while sitting or supine
  8. Glucose < 50 mg/dl (2.78 mmol/l) or > 400 mg/dl (22.22 mmol/l)
  9. Bleeding diathesis including platelets < 100,000, PT > 15 sec (INR > 1.4) or elevated PTT > upper limits of the normal range.
  10. Clinical presentation consistent with acute myocardial infarction (MI) or post-MI pericarditis that requires evaluation by cardiology prior to treatment
  11. Stroke, major head trauma, or intracranial surgery within the past 3 months
  12. Major surgery or parenchymal biopsy within 10 days (relative contraindication)
  13. Gastrointestinal or urinary bleeding within 21 days (relative contraindication)
  14. Arterial puncture at noncompressible site or lumbar puncture within 7 days (relative contraindication). Patients who have had a cardiac catheterization via a compressible artery are not excluded.
  15. Patient with malignancy or within 1 month of completion of treatment for cancer
  16. Patients with an underlying significant bleeding disorder. Patients with a mild platelet dysfunction, mild von Willebrand Disease or other mild bleeding disorders are not excluded.

Stroke related exclusions:

  1. Mild deficit (PedNIHSS < 6) at start of tPA infusion
  2. Severe deficit suggesting very large territory stroke, with pre-tPA PedNIHSS > 25, regardless of the infarct volume seen on neuroimaging
  3. Stroke suspected to be due to subacute bacterial endocarditis, moyamoya, sickle cell disease, meningitis, bone marrow, air or fat embolism
  4. Previously diagnosed primary angiitis of the central nervous system (PACNS) or secondary CNS vasculitis. Focal cerebral arteriopathy (FCA) of childhood is not a contraindication.

Neuro-imaging related exclusions:

  1. Intracranial hemorrhage (HI-1, HI-2, PH-1 or PH-2) on pretreatment head MRI or head CT
  2. Intracranial dissection (defined as at or distal to the opthalmic artery)
  3. Large infarct volume, defined by the finding of acute infarct on MRI involving 1/3 or or more of the complete MCA territory involvement, regardless of the pre-tPA PedNIHSS score due to increased risk of ICH.78, 79

Drug Related exclusions:

  1. Known allergy to recombinant tissue plasminogen activator
  2. Patient on anticoagulation therapy must have INR ≤ 1.4
  3. Patient who received heparin within 4 hours must have aPTT in normal range
  4. LMWH within past 24 hours (aPTT and INR will not reflect LMWH effect)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01591096

United States, California
Stanford University and Lucile Packard Children's Hospital at Stanford
Palo Alto, California, United States, 94304
United States, Colorado
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
United States, Maine
Massachusetts General Hospital
Boston, Maine, United States, 02114
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15244
United States, Tennessee
Monroe Carell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee, United States, 37232
United States, Texas
Children's Medical Center at Dallas
Dallas, Texas, United States, 75390-9063
Cook Children's Medical Center
Fort Worth, Texas, United States, 76104
University of Texas Medical School at Houston
Houston, Texas, United States, 77030
United States, Utah
The University of Utah and Primary Children's Medical Center
Salt Lake City, Utah, United States, 84113
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Canada, Alberta
Alberta Children's Hospital
Calgary, Alberta, Canada, T3B 6A8
Canada, Ontario
Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1E2
Sponsors and Collaborators
Seattle Children's Hospital
The Hospital for Sick Children
Medical College of Wisconsin
University of Texas at Austin
Alberta Children's Hospital
McMaster University
Principal Investigator: Catherine Amlie-Lefond, MD Seattle Children's Hospital
  More Information

No publications provided by Seattle Children's Hospital

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Catherine Amlie-Lefond, Associate Professor of Neurology, Seattle Children's Hospital Identifier: NCT01591096     History of Changes
Other Study ID Numbers: 1R01NS065818
Study First Received: May 1, 2012
Last Updated: February 10, 2014
Health Authority: United States: Food and Drug Administration
United States: Data and Safety Monitoring Board

Keywords provided by Seattle Children's Hospital:

Additional relevant MeSH terms:
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Nervous System Diseases
Vascular Diseases
Tissue Plasminogen Activator
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on October 08, 2015